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The authors have recently notified us of an error in the above
paper. It had come to their attention that, due to a coding error, a
number of patients who received chemotherapy or radiotherapy
were misclassified as having no treatment. The proportions of
patients receiving any chemotherapy, radiotherapy and any active
treatment were too low as reported. The median percentage and
range of patients receiving different treatments within the health
authorities are shown below in the revised Table 3.
In the revised analyses, there was still evidence of health
authority level variation in treatment and survival similar to that
shown in Figure 1. The associations of area and health service
characteristics are shown in the revised Table 5. There were no
material changes in the associations of survival with all area and
health service characteristics. In the analysis of determinants of
chemotherapy, radiotherapy and any treatment, the associations of
treatment with the lung cancer incidence rates were sensitive to
correction of the error.
The main conclusion of the paper that there is significant
geographical variation in the treatment of lung cancer, which may
be associated with differential access to oncology services, is still
supported.
Table 3 (revised) Median percentage and range of lung cancer patients
with each treatment by health authority, 1995–1999
Med % Range
None registered
a 38 32–55
Chemotherapy only (Chem) 10 6–17
Radiotherapy only (RT) 32 25–44
Non-investigative surgery only (S) 6 4–10
Chem+RT 9 5–14
S+Chem 0 0–1
S+RT 1 0–3
S+Chem+RT 0 0–1
Investigative surgery only 20 15–40
Any Chem 20 14–29
Any RT 42 31–54
Any S 7 5–12
Any treatment
b 62 45–68
First hospital visited a radiotherapy centre 27 8–79
aIncludes patients who had investigative surgery only.
bAny treatment¼any
chemomerapy, radiotherapy or non-investigative surgery.
Table 5 (revised) Area and organisational characteristics associated with
treatment and survival
OR 95% CI P-value
Any treatment
First hospital visited a radiotherapy centre 1.84 1.46–2.32 o0.0001
Deprivation (Townsend score) 0.98 0.96–0.99 0.0091
Age standardised incidence (per 100000) 1.00 0.99–1.01 0.9128
Any chemotherapy
First hospital visited a radiotherapy centre 1.24 0.98–1.55 0.0699
Deprivation (Townsend score) 0.96 0.94–0.98 0.0001
Age standardised incidence (per 100000) 1.02 1.01–103 0.0018
Any radiotherapy
First hospital visited a radiotherapy centre 1.67 1.32–2.10 o0.0001
Deprivation (Townsend score) 1.00 0.99–1.02 0.7759
Age standardised incidence (per 100000) 1.00 0.99–1.01 0.9748
Any non-investigate surgery
First hospital visited a radiotherapy centre 1.02 0.63–1.64 0.9383
Deprivation (Townsend score) 0.98 0.95–1.01 0.1206
Age standardised incidence (per 100000) 0.97 0.96–0.99 0.0005
1-year survival
a
First hospital visited a radiotherapy centre 1.18 0.96–1.45 0.1146
Deprivation (Townsend score) 1.01 1.00–1.03 0.0827
Age standardised incidence (per 100000) 0.99 0.98–1.00 0.0208
3-year survival
a
First hospital visited a radiotherapy centre 1.19 0.99–1.43 0.0674
Deprivation (Townsend score) 1.01 1.00–1.03 0.1320
Age standardised incidence (per 100000) 0.99 0.98–1.00 0.0276
Odds ratios adjusted for sex, age group, histology and stage of tumour, deprivation,
lung cancer incidence, whether first hospital attended was a radiotherapy centre and
hospital fitted as random effect.
aAlso adjusted for active treatment.
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